Slowly, But Surely, Gyrus Builds a Specialty Surgery Business
Executive SummaryOver the past two years, UK-based Gyrus Group has been transforming from an electromedical business built on its PlasmaKinetic technology into a more focused surgical device play focusing on tissue management and, more specifically, head and neck surgery.
You may also be interested in...
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.